Ocular toxicity due to Trametinib and Dabrafenib
Stephanie Sarny1, Michael Neumayer2, Julian Kofler3
1General Hospital Klagenfurt, Department of Opthalmology, Feschnigstraße 11, A-9020, Klagenfurt, Austria. stephanie.sarny@kabeg.at.
BMC Ophthalmology
|August 19, 2017
Summary
Patients on Trametinib and Dabrafenib for melanoma may experience eye problems like uveitis and neuroretinal detachment. Regular eye exams are crucial during this cancer treatment.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Metastatic cutaneous melanoma (stage IV) treatment often involves targeted therapies.
- Trametinib and Dabrafenib are BRAF and MEK inhibitors used in melanoma treatment.
- Ocular side effects can significantly impact patient quality of life.
Observation:
- A 66-year-old male patient presented with visual loss during Trametinib and Dabrafenib therapy.
- Ophthalmic evaluation revealed bilateral serous neuroretinal detachment and foveal white spots.
- Anterior uveitis occurred after drug discontinuation, recurring upon reinitiation without anterior chamber inflammation.
Findings:
- The case highlights a potential link between Trametinib/Dabrafenib therapy and specific ocular inflammatory and structural changes.
- Neuroretinal detachment recurred upon re-challenge with the medication.
- Ocular findings suggest a complex interaction between the targeted therapy and the visual system.
Implications:
- Ophthalmologists and oncologists should be vigilant for ocular adverse events in patients receiving Trametinib and Dabrafenib.
- Routine ophthalmic monitoring is recommended for patients undergoing this treatment regimen.
- Early detection and management of ocular side effects may prevent irreversible vision loss.
Related Concept Videos
01:24Drug Toxicity: Risk factors
55
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
55
01:24Drug Toxicity: Dose-Dependent Reactions
51
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
51
01:00Drug Toxicity: Overview
67
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
67
01:30Drug Toxicity: Allergic Reactions
58
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
58
01:30Drug toxicity: Drug–Drug Interaction
80
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
80
01:16Drug toxicity: Idiosyncratic Reactions
62
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
62